Wellington Partners leads €15m round for Definiens

Gilde Healthcare co-led the round, which also saw involvement from existing investors Cipio Partners and TVM Capital.

The fresh capital will enable Definiens to expand its activities to include digital tissue diagnostics. It will also support increased marketing activity intended to facilitate partnerships with global medical centres and pharmaceutical companies.

Wellington's contribution to the round was drawn from the Wellington Partners IV Life Science Fund, a 2012 vehicle that closed on €85m in September 2013, according to unquote" data.

Previous funding
In October 2012, Gilde Healthcare led a €10m funding round for Definiens, alongside existing backers TVM, Cipio and management.

Company
Definiens is a Munich-based company that develops image analysis technology for use in digital tissue diagnostics for cancer. Its products are predominantly used for research and development by pharmaceutical companies, but increasingly in tissue-based diagnostic biomarker development. The company was founded in 1994.

People
Professor Gerd Binnig is founder of Definiens, while Thomas Heydler is CEO and Dr Gerald Möller is the company's chairman. Rainer Strohmenger is general partner and managing director at Wellington and will take a seat on the board at Definiens. Janke Dittmer is a partner at Gilde Healthcare and already has a seat on the company's board.

Advisers
Company – GP Bullhound, Manish Madhvani, Alessandro Casartelli (Corporate finance). 

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• DACH
• Technology
• Wellington Partners
• Germany